Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialGlobeNewsWire • 04/08/24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/21/24
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data ReportedGlobeNewsWire • 03/12/24
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumGlobeNewsWire • 02/22/24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid TumorsGlobeNewsWire • 01/17/24
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access EventGlobeNewsWire • 01/04/24
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for CancerGlobeNewsWire • 12/13/23
Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023GlobeNewsWire • 11/28/23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewsWire • 11/06/23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/03/23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewsWire • 11/03/23
Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsGlobeNewsWire • 10/17/23
Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023GlobeNewsWire • 10/12/23
Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023GlobeNewsWire • 10/09/23
Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 10/05/23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and ImmunotherapyGlobeNewsWire • 10/04/23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 10/04/23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical TrialGlobeNewsWire • 10/03/23
Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and ImmunotherapyGlobeNewsWire • 09/25/23
Kineta Announces New Research Agreement to Evaluate VISTA Biomarker ExpressionGlobeNewsWire • 09/18/23